内脏脂肪与ADPKD进展:TEMPO 3:4试验队列研究
本研究基于TEMPO 3:4试验中1053例高危快速进展的ADPKD患者,利用深度学习从冠状位MRI提取内脏脂肪量。结果显示,内脏脂肪最高三分位与TKV年变化≥7%的 odds 显著增加相关(OR 4.78),女性关联更强;内脏脂肪越高,托伐普坦降低TKV增长的疗效越弱;在正常BMI患者中,内脏脂肪可改善快速进展的预测分类。
要点
- 内脏脂肪最高三分位者TKV年变化≥7%的OR为4.78,女性关联更强。
- 内脏脂肪越高,托伐普坦对TKV增长的抑制作用越弱。
- 正常BMI患者中,内脏脂肪可改善快速进展的预测分类。
核心结论
- MRI冠状位深度学习量化的内脏脂肪独立关联ADPKD患者更快的肾脏增长,并改善正常BMI者的快速进展分类。
- 内脏脂肪越高,托伐普坦降低TKV增长的疗效越弱。
研究设计与样本
- 回顾性队列研究,纳入TEMPO 3:4托伐普坦试验中1053例高危快速进展的ADPKD患者。
- 预测因子为深度学习从冠状位MRI提取的内脏脂肪估计值。
主要发现
- 完全校正模型中,内脏脂肪最高三分位与TKV年变化≥7%相比<5%的OR为4.78(95%CI 3.03-7.47)。
- 该关联在女性中强于男性(交互P<0.01)。
- 线性混合模型中,托伐普坦疗效随内脏脂肪增加而降低(治疗×时间×内脏脂肪三阶交互P=0.002)。
- 内脏脂肪改善正常BMI者预测TKV年百分比快速变化的分类性能(DeLong检验z=-2.03,P=0.04)。
- 总体队列中内脏脂肪与eGFR斜率无关;女性中内脏脂肪每增加10单位与eGFR斜率快速下降(低于中位数)相关(OR 1.06,95%CI 1.01-1.11),男性无此关联(OR 0.98,95%CI 0.95-1.02)。
临床怎么用
- 对ADPKD患者可考虑利用冠状位MRI深度学习量化内脏脂肪,辅助识别快速进展高风险者,尤其正常BMI者。
- 内脏脂肪较高的患者托伐普坦疗效可能减弱,临床决策时需综合评估。
局限性
- 回顾性研究。
- 仅纳入快速进展者。
- 深度学习计算需求较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Body mass index (BMI) is an independent predictor of kidney disease progression in individuals with autosomal dominant polycystic kidney disease (ADPKD). Adipocytes do not simply act as a fat reservoir but are active endocrine organs. We hypothesized that greater visceral abdominal adiposity would associate with more rapid kidney growth in ADPKD and influence the efficacy of tolvaptan. STUDY DESIGN: A retrospective cohort study. SETTING & PARTICIPANTS: 1,053 patients enrolled in the TEMPO 3:4 tolvaptan trial with ADPKD and at high risk of rapid disease progression. PREDICTOR: Estimates of visceral adiposity extracted from coronal plane magnetic resonance imaging (MRI) scans using deep learning. OUTCOME: Annual change in total kidney volume (TKV) and effect of tolvaptan on kidney growth. ANALYTICAL APPROACH: Multinomial logistic regression and linear mixed models. RESULTS: In fully adjusted models, the highest tertile of visceral adiposity was associated with greater odds of annual change in TKV of≥7% versus<5% (odds ratio [OR], 4.78 [95% CI, 3.03-7.47]). The association was stronger in women than men (interaction P<0.01). In linear mixed models with an outcome of percent change in TKV per year, tolvaptan efficacy (% change in TKV) was reduced with higher visceral adiposity (3-way interaction of treatment ∗ time ∗ visceral adiposity, P=0.002). Visceral adiposity significantly improved classification performance of predicting rapid annual percent change in TKV for individuals with a normal BMI (DeLong's test z score: -2.03; P=0.04). Greater visceral adiposity was not associated with estimated glomerular filtration rate (eGFR) slope in the overall cohort; however, visceral adiposity was associated with more rapid decline in eGFR slope (below the median) in women (fully adjusted OR, 1.06 [95% CI, 1.01-1.11] per 10 unit increase in visceral adiposity) but not men (OR, 0.98 [95% CI, 0.95-1.02]). LIMITATIONS: Retrospective; rapid progressors; computational demand of deep learning. CONCLUSIONS: Visceral adiposity that can be quantified by MRI in the coronal plane using a deep learning segmentation model independently associates with more rapid kidney growth and improves classification of rapid progression in individuals with a normal BMI. Tolvaptan efficacy decreases with increasing visceral adiposity. PLAIN-LANGUAGE SUMMARY: We analyzed images from a previous study with the drug tolvaptan conducted in patients with autosomal dominant polycystic kidney disease (ADPKD) to measure the amount of fat tissue surrounding the kidneys (visceral fat). We had previously shown body mass index can predict kidney growth in this population; now we determined whether visceral fat was an important factor associated with kidney growth. Using a machine learning tool to automate measurement of fat in images, we observed that visceral fat was independently associated with kidney growth, that it was a better predictor of faster kidney growth in lean patients than body mass index, and that having more visceral fat made treatment of ADPKD with tolvaptan less effective.
引用
- Nowak KL, Moretti F, Bussola N, et al. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial. Am J Kidney Dis. 2024. PMID: 38608748. doi:10.1053/j.ajkd.2024.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。